Searched over 200M research papers
10 papers analyzed
These studies suggest that elevated serum ACE levels are associated with active sarcoidosis and can aid in diagnosis and monitoring, but normal levels do not rule out the condition and further examinations may be needed.
20 papers analyzed
Sarcoidosis is a granulomatous disease characterized by the formation of immune cell clusters called granulomas in various organs, most commonly the lungs. One of the key biomarkers for diagnosing and monitoring sarcoidosis is the serum angiotensin-converting enzyme (ACE) level. Elevated ACE levels are often associated with active sarcoidosis and can aid in distinguishing it from other diseases.
Research consistently shows that patients with active sarcoidosis exhibit significantly elevated serum ACE levels. In a study involving 17 patients with active sarcoidosis, 15 showed elevated ACE levels, which were more than two standard deviations above the mean for adult control subjects. This elevation is not typically seen in other granulomatous diseases, making it a specific marker for sarcoidosis .
The diagnostic utility of ACE levels has been further validated in larger cohorts. A retrospective study of 3,781 subjects found that the serum ACE levels were significantly higher in patients with sarcoidosis compared to those without the disease (19.6 IU/L vs. 10.7 IU/L, respectively). The study proposed a new cut-off value of 14.7 IU/L for diagnosing sarcoidosis, which improved sensitivity and specificity compared to the traditional cut-off.
Longitudinal studies have demonstrated that serum ACE levels correlate well with the clinical status of sarcoidosis patients. Changes in ACE levels were found to be predictive of disease activity and therapeutic response, making it a valuable tool for monitoring the disease course . For instance, a study involving 31 patients over two to four years showed that ACE levels correlated best with clinical status and gallium scans, which are used to localize disease involvement.
The ACE gene polymorphism, specifically the insertion (I)/deletion (D) polymorphism, affects serum ACE levels. There are three genotypes: DD, DI, and II, with the highest ACE levels observed in the DD genotype. Studies have shown that this polymorphism is associated with serum ACE levels in both sarcoidosis patients and healthy controls . However, no significant differences in genotype distribution were found between sarcoidosis patients and controls, suggesting that while the polymorphism affects ACE levels, it may not be a direct risk factor for sarcoidosis .
Elevated serum ACE levels can be used to monitor the effectiveness of treatment in sarcoidosis patients. For example, corticosteroid therapy has been shown to reduce elevated ACE levels to normal ranges, indicating disease resolution or control . Serial measurements of ACE can thus help in adjusting therapeutic strategies and predicting relapses .
While elevated ACE levels are a useful diagnostic tool, they are not exclusive to sarcoidosis. Conditions like Gaucher's disease can also present with elevated ACE levels, although they can be distinguished by other biomarkers such as serum acid phosphatase. Additionally, normal ACE levels do not rule out sarcoidosis, as some patients with the disease may have ACE levels within the normal range.
Elevated serum ACE levels are a significant biomarker for diagnosing and monitoring sarcoidosis. They provide valuable insights into disease activity and therapeutic response, although their specificity is not absolute. Understanding the genetic factors influencing ACE levels and their correlation with clinical status can enhance the management of sarcoidosis, making ACE a crucial component in the diagnostic and therapeutic arsenal against this complex disease.
Most relevant research papers on this topic